DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) President & CEO Saiid Zarrabian sat down with Proactive's Christine Corrado at BIO CEO in New York. The San Diego, California-based company is focused on developing new therapies for cancer patients. Its current pipeline is based around VAL-083, a small-molecule chemotherapeutic that has demonstrated clinical activity against a range of cancers.
DelMar Pharmaceuticals talks through Phase 2 data published in peer-reviewed journal 'Glioma'
Quick facts: Kintara Therapeutics
Price: 1.98 USD
Market Cap: $60.64 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE